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Society for Vascular Surgery position statement:
Comparative effectiveness research in vascular
disease managementOVERVIEW
The Society for Vascular Surgery (SVS) applauds the
recent federal commitment to improve the lives of patients
through studies to determine the most effective treatments
for a broad range of medical conditions. Attention to health
care cost containment is essential to maintain the superior-
ity of our health care system. In view of the rapid growth of
the elderly population, the demographic segment in whom
vascular disease predominates, we believe that vascular dis-
ease represents a very important area for objective research.
Currently, 12 million Medicare beneficiaries are being
treated for peripheral arterial disease at a cost of approxi-
mately $151 billion. Therefore, the SVS fully endorses the
concept of comparative effectiveness research, has a dem-
onstrated record of expertise and commitment to this pro-
cess, including defining and publishing peer-reviewed prac-
tice guidelines, and is eager to participate actively in the
design and implementation of these studies as they relate to
vascular ailments.
The SVS endorses the full evaluation of all clinical
options for the treatment of vascular disease to ensure that
the highest possible quality of care is available to patients.
The SVS believes that comparative effectiveness initiatives
in vascular disease should begin by addressing these areas of
priority:
● Carotid disease. Stroke is the third leading cause of
death, the second leading cause of dementia, and the
leading cause of adult disability in the United States. Fur-
ther, the prevalence of stroke increased exponentially
among those aged 65 years, and especially those aged
75, the fastest growing segment of the population. Ca-
rotid artery occlusive disease is a common and preventable
cause of ischemic stroke. Large randomized controlled
trials have previously established the appropriate indica-
tions for carotid endarterectomy. However, evolving and
improving medical therapy and the introduction of endo-
vascular carotid angioplasty and stenting have complicated
the question of the optimal treatment for the patient with
carotid artery disease, especially in individuals with asymp-
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needed in this area.
● Lower extremity occlusive disease. In recent years
we have witnessed the rapid development and adoption of
minimally invasive and expensive technologies to treat
lower extremity arterial disease despite a paucity of critical
data supporting clinical effectiveness and cost efficacy. This
has led to an environment where patients and providers are
not sufficiently informed to decide what the best and most
cost-effective treatment modality is in a particular case. The
SVS believes that nonoperative, endovascular, and opera-
tive treatment strategies should be closely examined within
the context of comparative effectiveness.
●Venous disease. The treatment of venous reflux and
obstructive disease represents an understudied aspect of
venous disease, and yet in recent years, we have seen an
exponential growth in the performance of minimally inva-
sive new technologic procedures to treat this very common
clinical disorder. The importance of venous disease as a
topic of study lies in its prevalence and the overall lack of
high-quality comparative data. In addition, patients with
venous disease represent a younger cohort compared with
those with arterial disease. These patients often suffer from
substantial morbidity that likely carries a significant societal
burden with lost workdays and long-term disability.
THE ROLE OF THE SVS
To help promote an understanding of comparative
effectiveness research among clinicians, the SVS com-
mits to:
● providing formal education to its members about com-
parative effectiveness research so that vascular sur-
geons can participate in such studies and successfully
use the results to improve patient care;
● continuing development of practice guidelines, re-
porting standards, and quality measures that can form
the foundation of comparative effectiveness research;
● urging the publishers of vascular studies to embrace
the methodologies of comparative effectiveness re-
search and insist that research articles be based on
high-quality evidence;
● studying the role of comparative effectiveness research
in maintenance of certification activities;
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 6 Stoner et al 1593● working to ensure that the Vascular Registry contains
data elements conducive to comparative effectiveness
research;
● encouraging open dialogue with other professional
societies regarding comparative effectiveness initia-
tives;
● working with payors to document and promote com-
parative effectiveness research; and to
● working with the medical industry to establish guide-
lines for studying clinical and cost efficacy of new
technologies and treatments.
CONCLUSION
The SVS supports the promotion of high-quality, data-
driven vascular care. We believe that comparative effective-
ness research plays an important role in the development ofa more sustainable American health care system and can
significantly improve the health of patients, their families,
and their communities. We believe that collaboration be-
tween practitioners and payors, including the federal gov-
ernment, is appropriate and essential to conducting the
necessary high quality research to optimize patient care in
the future in the most cost effective fashion. The SVS is
uniquely poised to lead in this process.
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